InvestorQ : Why has Pfizer scaled back on its production targets for the COVID vaccines?
Moii Chavate made post

Why has Pfizer scaled back on its production targets for the COVID vaccines?

Tisha Malhotra answered.
5 months ago

For Pfizer, it appears to be more of a case of logistic and supply chain issues that is forcing them into this decision. In fact, Pfizer has scaled back on its Covid-19 production targets after it ran into difficulties securing all the requisite materials needed to produce the shots on a fairly large scale.

Pfizer had originally aimed to manufacture up to 100 million vaccine doses this year but has now apparently cut that to an estimate of up to 50 million doses. It may be recollected that Pfizer is developing its vaccine with BionTech of Germany. According to the company, the long time it took to procure materials was instrumental in this decision.

However, Pfizer remains confident of its ability to supply up to 1.3 billion doses by the end of the year 2021. The vaccine candidate will be a two-shot vaccine, based on a technology called messenger RNA. This technology was cleared by the UK regulators last week and has also been submitted to the USFDA for emergency use authorization.

In a nutshell, the global market is relying on mass manufacturing at an unprecedented speed and scale in order to end the pandemic. However, there are real issues like supply chains, transportation, storage, freezing etc that may pose irritants along the way. By end of 2021, the US expects to distribute 40 million vaccine doses to cover 20 million people.

Both the US and UK are lowering their expectations from the vaccine to ensure their demand is more in tune with what is really pragmatic.